Cardiometabolic remodeling : mechanisms and microenvironnement (CERAMIC)
The focus of our research program is to delineate the molecular mechanisms that govern cardiac remodeling processes and to translate these discoveries into new diagnostic and therapeutic strategies for heart failure (HF). Fibrosis, inflammation and metabolic abnormalities are major aspects of cardiac remodeling and ventricular dysfunction leading to the development and progression of HF. This is currently the central axis of our research projects that combine the expertise of clinical and academic researchers. A specific focus of our studies is to understand how metabolism regulates myocyte and stroma cell functions and how to exploit metabolic changes for therapeutic benefits to prevent adverse cardiac remodeling. We combine state-of-the-art « omics » technologies with mainstay techniques of molecular biology, cell biology, biochemistry, (patho)physiology and pharmacology to identify and characterize new actors and networks in cardiovascular biology. The translational research programs of our team foster the multidisciplinary integration of basic- and patient-oriented research, moving from bench to bedside.
Tél/Phone:+33(0)5 31 22 41 17
Associate Professor in physiology at the Faculty of Pharmaceuticals sciences, Toulouse
In vivo studies, in preclinical models, of cardiac remodeling associated with various cardiac pathologies, of its molecular actors and of the means of intervention on the identified therapeutic targets.
Yannis Sainte-Marie has a PhD in Biology from the Paris VII University, France, in 2006 for his work on new roles for the mineralocorticoid receptor in physiopathology. After a post-doctoral project on molecular actor of heart failure, he was recruited as assistant professor in Physiology at the Faculty of Pharmaceuticals sciences and joined the team in 2010.
Main domains of expertise
Cardiac physiopathology, animal model design and phenotypic characterization.
Sourour BEN HARZALLAH
Expert in Cell biology and imaging technics. She develops tools allowing the study of signaling pathways on cultured vascular cells and tissues.
Master’s degree in cell biology and physiology (2003-2004). Hired at Paul Sabatier University in 2005 and at INSERM in 2012.
Main domains of expertise
Signalisation, Biologie cellulaire et moléculaire, Imagerie, Cytométrie en flux
Metabolic reprogramming of stromal cells in cardiac remodeling and impact on the inflammatory microenvironment
Coordinators : O. Kunduzova, F. Savagner, V. Poinsot, D. Cussac, A. Parini
Through our research program we aim to characterize the metabolic reprogramming of fibroblast-to-myofibroblast transition in myocardial fibrotic remodeling, to define the metabolic profile of cardiac mesenchymal stromal cells in relation to their secretory activities and to establish their links with immunoinflammatory cells in HF predisposing conditions (pressure overload, obesity, aging).
Phosphoinositides metabolism in cardiac remodeling
Coordinators : F. Boal, H. Tronchère, O. Kunduzova
Our research focuses on the role of the rare phosphoinositide phosphatidylinositol 5-phosphate (PI5P) in cardiac remodeling. More specifically, we aim to decipher the involvement of its biosynthetic pathways in fibrotic and cardiometabolic remodeling. In particular, we investigate the role of the lipid kinase PIKfyve and the phosphatase myotubularin MTM1 in cardiomyocytes metabolic alterations and activation of cardiac fibroblasts during the progression of heart failure.
Translation to clinical research
Coordinators : J. Roncalli, C. Laborde, A. Parini
The translational part of our project concerns two major Axes: 1) the design of novel strategies targeting at challenges of cardiac regenerative medicine and 2) the identification of novel therapeutic targets and biomarkers of cardiac dysfunction associated with obesity and aging. Our group has a large experience on the approaches of cardiac cell therapy using bone marrow mesenchymal stem cells (BM-MSCs). In addition, we have developed an alternative strategy based on the design of bioengineered BM-MSCs/biomatrices providing the local delivery of beneficial paracrine factors without major side effects related to intramyocardial injection.
Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling. Cinato M, Guitou L, Saidi A, Timotin A, Sperazza E, Duparc T, Zolov SN, Giridharan SSP, Weisman LS, Martinez LO, Roncalli J, Kunduzova O, Tronchere H, Boal F. Theranostic. 2021. Pubmed
Galanin promotes autophagy and alleviates apoptosis in the hypertrophied heart through FoxO1 pathway. Martinelli I, Timotin A, Moreno-Corchado P, Marsal D, Kramar S, Loy H, Joffre C, Boal F, Tronchere H, Kunduzova O. Redox Biol. 2021. Pubmed
Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction. Abbadi D , Laroumanie F, Bizou M, Pozzo J, Daviaud D, Delage D, Calise D, Gaits-Iacovoni F, Dutaur M, Tortosa F, Renaud-Gabardos E , Douin-Echinard V, Prats A.C, Roncalli J, Parini A, and Pizzinat N Cardiovasc Res. 2018.Pubmed
Inserm/UPS UMR 1297 - I2MC Institut des Maladies Métaboliques et Cardiovasculaires
1 avenue Jean Poulhès - BP 84225 - 31432 Toulouse Cedex 4
Tél. : 05 61 32 56 00
Du lundi au vendredi
8h30 - 12h30 / 13h45 -16h45